Change of Adviser
3 December 2010
Preliminary Results 2010
23 November 2010
Sativex Enters Phase III Clinical Programme In Cancer Pain
23 November 2010
Sativex Approved in New Zealand for the Treatment of Spasticity due to Multiple Sclerosis
3 November 2010
Notification of Results
21 October 2010
Sativex® Phase III Data Presented at ECTRIMS Congress
14 October 2010
GW Starts Phase IIa Study Programme Evaluating New Cannabinoid Medicines In Type 2 Diabetes
30 September 2010
Promising Phase II Clinical Study Results of Sativex in MS Bladder Dysfunction Published in Peer Review Journal
22 September 2010
Health Canada Grants Full Approval of Sativex For the Treatment of Spasticity Due to Multiple Sclerosis
31 August 2010
Sativex® receives regulatory authorisation in Spain
28 July 2010
GW Appoints Tom Lynch as Non-Executive Director
27 July 2010
Clarification re media comment
2 July 2010
GW and Otsuka Agree Three Year Extension to Global Cannabinoid Research Collaboration
30 June 2010
GW Pharmaceuticals to present at the 5th Annual Piper Jaffray Europe Healthcare Conference
22 June 2010
GW announces UK launch of world’s first prescription cannabis medicine
21 June 2010
Interim Results For The Six Months Ended 31 March 2010
20 May 2010
Positive data in Sativex® Phase IIb trial support advancing into Phase III development in cancer pain
23 March 2010
Sativex Update - UK and Spanish regulators confirm no major issues - Approvals expected Q2 2010.
18 March 2010
